HIGHLIGHTS
- who: POSTER PRESENTATION et al. from the (UNIVERSITY) have published the paper: Management of stage 1 TTR FAP: French experience, in the Journal: (JOURNAL)
- what: Treatment of stage 1 TTR-FAP by tafamidis requires a close and long term monitoring of patients including a detailed questionnaire on walking disability, autonomic dysfunction, extension of pain and sensory loss.
SUMMARY
Transthyretin Familial Amyloid Polyneuropathy (TTRFAP) is a worldwide autosomal dominant disease due to point mutation of TTR gene. The main endemic area is Portugal, associated with V30M variant and an early onset (EO . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.